NCT06731270View on ClinicalTrials.gov

Diclofenac for the Treatment of Patients With Metastatic Non-small Cell Lung Cancer on Single Agent Immunotherapy

PHASE2RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

April 9, 2025

Primary Completion Date

January 1, 2026

Study Completion Date

January 1, 2027

Conditions
Advanced Lung Non-Small Cell CarcinomaMetastatic Lung Non-Small Cell CarcinomaStage III Lung Cancer AJCC v8Stage IV Lung Cancer AJCC v8
Interventions
BIOLOGICAL

Atezolizumab

Given atezolizumab

PROCEDURE

Biospecimen Collection

Undergo blood sample collection

BIOLOGICAL

Cemiplimab

Given cemiplimab

PROCEDURE

Computed Tomography

Undergo CT

DRUG

Diclofenac Potassium

Given PO

OTHER

Electronic Health Record Review

Ancillary studies

PROCEDURE

Magnetic Resonance Imaging

Undergo MRI

BIOLOGICAL

Nivolumab

Given nivolumab

BIOLOGICAL

Pembrolizumab

Given pembrolizumab

PROCEDURE

Positron Emission Tomography

Undergo PET

Trial Locations (2)

30308

RECRUITING

Emory University Hospital Midtown, Atlanta

30322

RECRUITING

Emory University Hospital/Winship Cancer Institute, Atlanta

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Emory University

OTHER